Annual Summary of Stock Exchange Releases published in 2009
Orion
Corporation - Stock Exchange Release
ORION CORPORATION: Annual Summary of Stock
Exchange Releases published in 2009
ORION CORPORATION STOCK EXCHANGE RELEASE 20 JAN 2010
AT 12.30 EET
In accordance with Chapter 2, Section 10 c
of the Finnish Securities Market Act, Orion Corporation publishes an Annual
Summary of the stock exchange releases published by the company in 2009. The
releases are available on the internet website of Orion Corporation, at http://www.orion.fi/sereleases.
Orion points out that part of the
information in the releases can have become out-dated.
Stock
Exchange Releases in 2009
|
Jan 7th 2009
|
Orion's statutory negotiations completed.
Personnel to be reduced by about 205 in Finland
|
|
Jan 15th 2009
|
Orion sues Wockhardt USA LLC and Wockhardt
Limited in the U.S. to enforce Orion's U.S. Patents covering its proprietary
drug Stalevo®
|
|
Jan 16th 2009
|
Orion: Annual Summary of Stock Exchange
Releases and Announcements published in 2008
|
|
Jan 19th 2009
|
Orion publishes 2008 Financial Statement
release on 6 Feb 2009
|
|
Jan 28th 2009
|
Recommendation by the Nomination Committee
concerning Board of Directors to be elected by the 2009 AGM of Orion
Corporation
|
|
Feb 6th 2009
|
Orion Group Financial Review of 2008
|
|
Feb 6th 2009
|
Matters to be handled at the AGM of Orion
Corporation on 23 March 2009
|
|
Feb 24th 2009
|
Orion: Primary objective of STRIDE-PD study
was not achieved
|
|
Mar 4th 2009
|
Orion Group Annual Report 2008 published
|
|
Mar 5th 2009
|
Orion Corporation: Transfer of 44,806 own
B-shares
|
|
Mar 6th 2009
|
Orion withdraws EU application for extending
the indication of Stalevo®
|
|
Mar 23rd 2009
|
Orion Corporation: Decisions by the AGM on 23
March 2009
|
|
Mar 23rd 2009
|
Orion Corporation: Jukka Ylppö Vice Chairman
of the Board of Directors. Compositions of Board committees
|
|
Apr 14th 2009
|
Amendments to Orion's Articles of Association
entered in the Trade Register
|
|
Apr 20th 2009
|
Orion invites to a Q1 news conference on
Monday 27 April 2009
|
|
Apr 27th 2009
|
Orion Group Interim Report 1-3/2009
|
|
Apr 29th 2009
|
Orion and Wockhardt settle patent dispute
|
|
May 6 2009
|
Orion reacquires rights for i.v. levosimendan
(Simdax®)
|
|
Jun 10th 2009
|
Orion invites analysts and media to Q2 news
conference on Friday 7 August 2009
|
|
Jul 31st 2009
|
Orion comments on ANDA filed by Sandoz Inc.
for a generic version of Orion's proprietary drug Precedex® (dexmedetomidine
hydrochloride 100 mcg base/ml ) in the United States
|
|
Aug 7th 2009
|
Orion Group Interim Report January-June 2009
|
|
Aug 7th 2009
|
Orion: Correction to English version of
Interim Report 1-6/2009
|
|
Sep 4th 2009
|
Orion and Hospira,Inc. sue Sandoz companies
in the U.S. to enforce their U.S. Patents covering the proprietary drug
Precedex®
|
|
Sep 21st 2009
|
Composition of the Nomination Committee of
Orion Corporation
|
|
Oct 6th 2009
|
Orion invites analysts and media to Q3 news
conference on Monday 26 October 2009
|
|
Oct 21st 2009
|
Orion withdraws US application for extending
the indication of Stalevo®
|
|
Oct 26th 2009
|
Orion Corporation's publication schedules for
financial reporting in 2010
|
|
Oct 26th 2009
|
Orion Group Interim Report January-September
2009
|
|
Nov 27th 2009
|
100,000 Orion A-shares converted into
B-shares
|
|
Dec 4th 2009
|
Orion clarifies information emanating from
Capital Markets Day
|
Orion Corporation
Timo Lappalainen Olli Huotari
President and CEO SVP, Corporate Functions
Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo
Homepage: www.orion.fi
Orion
is an innovative European R&D-based pharmaceutical and diagnostic company
with a special emphasis on developing medicinal treatments and diagnostic tests
for global markets. Orion develops, manufactures and markets human and
veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic
tests. Orion's pharmaceutical R&D focuses on the following core therapy
areas: central nervous system drugs, cancer and critical care drugs, and
Easyhaler® pulmonary drugs.
The
Group's net sales in 2008 amounted to EUR 711 million. The Company
invested EUR 90 million in research and development. At the end of 2008, the
Group had a total of 3,300 employees, of whom 2,700 worked in Finland and 600
in other European countries. Orion's A and B shares are listed on NASDAQ OMX
Helsinki.
Archive
-
Jan 1st 2010 12:00 AM
-
Jan 1st 2006 12:00 AM
-
Jan 1st 2007 12:00 AM
-
Jan 1st 2008 12:00 AM
-
Jan 1st 2009 12:00 AM